Gilead Sciences, Inc. (FRA:GIS)

Germany flag Germany · Delayed Price · Currency is EUR
95.14
-0.04 (-0.04%)
At close: Jun 3, 2025
63.30%
Market Cap 119.53B
Revenue (ttm) 26.59B
Net Income (ttm) 5.52B
Shares Out n/a
EPS (ttm) 4.38
PE Ratio 21.66
Forward PE 13.28
Dividend 2.87 (3.02%)
Ex-Dividend Date Mar 14, 2025
Volume n/a
Average Volume 803
Open 95.14
Previous Close 95.18
Day's Range 95.14 - 95.14
52-Week Range 58.03 - 111.04
Beta n/a
RSI 53.35
Earnings Date Aug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 17,600
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol GIS
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

ASCENT-03: Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrati...

13 days ago - Wallstreet:Online

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The stud...

13 days ago - Business Wire

Final Trade: WMT, GILD, DECK, ROST

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

13 days ago - CNBC Television

Final Trade: WMT, GILD, DECK, ROST

The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.

13 days ago - CNBC

Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research

NORTHAMPTON, MA / ACCESS Newswire / May 20, 2025 / Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential...

16 days ago - Wallstreet:Online

Is this Gilead? Nope, just Georgia.

A brain-dead woman is being forced to carry a baby to term, and we are in hell.

20 days ago - The Washington Post

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society ...

20 days ago - Business Wire

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

NORTHAMPTON, MA / ACCESS Newswire / May 15, 2025 / "Living with primary biliary cholangitis (PBC) can be an isolating experience," explains Dilek, a mother of two from Germany who suffers from the rar...

20 days ago - Wallstreet:Online

Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities Health Care Conference May 13, 2025 2:20 PM ETCompany ParticipantsJohanna Mercier – Chief Commercial...

22 days ago - Seeking Alpha

The 2024 Responsible Business and Impact Report Shares How Gilead Sciences Is Driving Change

NORTHAMPTON, MA / ACCESS Newswire / May 13, 2025 / At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the plan...

23 days ago - Wallstreet:Online

US stocks close sharply higher on US China tariff news

The major US stock indices are sharply higher on US/China tariff news. Over the weekend the US slashed tariffs for the next 90-days on China goods from 145% to 30% inclusive of a 20% tariff due to fen...

23 days ago - Forexlive

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

23 days ago - CNBC Television

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...

23 days ago - Seeking Alpha

Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

27 days ago - CNBC Television

Earth Day Focus for Gilead Sciences - Every Action Has an Impact

NORTHAMPTON, MA / ACCESS Newswire / May 8, 2025 / Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to en...

4 weeks ago - Wallstreet:Online

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...

4 weeks ago - Benzinga

Gilead announces $11 billion in new investments in US

Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through...

4 weeks ago - Reuters

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of ...

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 | GILD Stock News

4 weeks ago - GuruFocus

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment –...

4 weeks ago - Benzinga

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with ch...

4 weeks ago - Business Wire